The synergistic effect of homocysteine and lipopolysaccharide on the differentiation and conversion of raw264.7 macrophages
© Gao et al.; licensee BioMed Central Ltd. 2014
Received: 4 March 2013
Accepted: 8 May 2014
Published: 13 May 2014
Macrophages play pivotal roles in the progression of atherosclerosis (AS) and their heterogeneous differentiation patterns have been studied extensively. The classical subtype of activated macrophage, M1, promotes the progression of AS. Conversely, the alternative subtype of activated macrophage, M2, is regarded as a repressor of AS. Homocysteine (Hcy) may influence macrophage subtype polarization both in vivo and in vitro. Homocysteinemia (HHcy) is an independent risk factor in coronary heart disease and the effect of Hcy on macrophage differentiation has not been studied until now.
Different concentrations of Hcy in combination with a fixed concentration of lipopolysaccharide (LPS, 200 ng/mL) were used to treat RAW264.7 macrophages. Real-time PCR was used to detect and quantify RNA transcripts indicative of M1 and M2 differentiation. The efficacy and specificity for each chemical stimulant in inducing macrophage differentiation were also investigated. The M2 macrophages (anti-inflammatory subtype) induced using classical methods (IL-4, 10 ng/mL) were also treated with different concentrations of Hcy complemented with LPS. The synergistic effect of Hcy and LPS in the converting the M2 subtype to M1 was also studied.
Macrophages can be induced to differentiate towards M1 by a combination of Hcy with LPS, with the strongest effect observed at an Hcy concentration of 50 μmol/L. After inducing macrophages to the M2 subtype using IL-4, treatment with both Hcy and LPS could elicit conversion from the M2 to M1 subtype.
Combined treatment with Hcy and LPS can induce the polarization of cultured RAW264.7 macrophages into the pro-inflammatory subtype, as well as promote subtype conversion from anti-inflammatory to pro-inflammatory.
KeywordsHomocysteine Lipopolysaccharide Macrophages M1/M2 subtype Polarization Subtype conversion
Atherosclerosis (AS) is a chronic and progressive inflammatory disease characterized by the accumulation of lipids and fibrous lesions in the large arterial intima. Mechanisms governing AS continue to draw extensive research interest. Among proposed mechanisms, the immuno-inflammation hypothesis has become accepted by most researchers[1–3]. Macrophages are important in both the initiation and progression of AS[4, 5]. Macrophages can differentiate into two subtypes (M1 and M2) in response to micro-environmental changes. Considered the classical activated subtype, M1 exerts pro-inflammatory effects that promote the progression of AS. In contrast, the M2 activated subtype exerts anti-inflammatory effects and is regarded as a repressor of AS[6, 7].
Hyperhomocysteinemia (HHcy, abnormally high physiological levels of homocysteine, Hcy) is regarded as an independent risk factor in coronary heart disease, although the exact mechanism of how Hcy induces AS is unclear. Studies have shown that Hcy can promote AS occurrence and progression through oxidative stress damage, endothelial damage, and activation of inflammatory and immune responses[8, 9]. A positive correlation between HHcy, endothelial dysfunction, and accelerated AS has been demonstrated by using gene-induced and diet-induced HHcy animal models. The results of some studies also reveal that Hcy could induce monocyte/macrophage localization in inflammatory lesions and exert pro-AS effects. Additionally, researchers have found that Hcy can influence the differentiation of macrophages both in vivo and in vitro. However, it is unclear if the effect of Hcy on macrophage polarization and subtype conversion correlates to its pathogenic role in AS.
Materials and methods
The RAW264.7 macrophage cell line was provided by the Cardiology Institute of the First Affiliated Hospital of Medical College, Xi’an Jiaotong University. RAW264.7 cells were cultured in DMEM supplemented with 10% (vol/vol) FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL). In a 6-well round bottom plate, 1 × 106 cells per well were seeded and incubated at 37°C for 12 hours. Before stimulation by Hcy and LPS, cells were serum-starved by culturing in DMEM without 10% FBS for 12 hours.
Sequences of real-time PCR primers
TCA ACG GCA CAG TCA AGG
ACT CCA CGA CAT ACT CAG C
AGC CAG AGT CCT TCA GAG AGA TAC
AAT TGG ATG GTC TTG GTC CTT AGC
GCT CTT CTG TCT ACT GAA CTT CGG
ATG ATC TGA GTG TGA GGG TCT GG
CCC TTC CGA AGT TTC TGG CAG CAG C
CCA AAG CCA CGA GGC TCT GAC AGC C
GGT TGC CAA GCC TTA TCG TA
ACC TGC TCC ACT GCC TTG CT
ATG CTC ACA CTG ACA TCA ACA CTC
CTC TTC CAT CAC CTT GCC AAT CC
CAT GAG GCT TCT CCT GCT TCT G
TTG CCG TCT GAA CTG AGA TGG
RNA isolation and real-time PCR
Total RNA was isolated with the RNA Fast 200 kit according to the manufacturer’s instructions. First-strand cDNA was synthesized with the RevertAid™ First Strand cDNA Synthesis Kit and analyzed by real-time quantitative PCR with SYBR Premix Ex Taq™ II. PCR was performed on the IQ5™ Multicolor real-time PCR and detection system (Bio-Rad, Hercules, CA, USA). Data were analyzed on the basis of relative expression method using the formula ΔΔC expression = 2–ΔΔCt, where ΔΔCt = ΔCt (treated group) – ΔCt (control group), ΔCt = Ct (target gene) – Ct (GAPDH), and Ct = cycle at which the threshold is reached.
Data were analyzed with SPSS for Windows (version 18.0) using one-way ANOVA. Unless otherwise stated, graphs show mean ± SD. For each dataset, p < 0.05 was considered statistically significant.
Effects of Hcy and LPS on mRNA expression in macrophages
Time effect of Hcy and LPS treatment on mRNA expression in macrophages
Effects of Hcy and LPS on mRNA expression in M2 macrophages
Time effect of Hcy and LPS on mRNA expression in M2 macrophages
Macrophages are considered to be important immune effector cells. Recent studies have uncovered plasticity and heterogeneity in their differentiation pathways, as demonstrated by changes in cellular phenotype and physiology in response to micro-environmental stimuli. Mirroring the Th1/Th2 nomenclature, polarized macrophages are categorized into M1 and M2 subtypes. The classical subtype of activated macrophages, M1, can initiate adaptive immune responses and produce various pro-inflammatory cytokines. These biochemical responses are often involved in killing microorganisms and tumor cells. Moreover, M1 macrophages can promote atherosclerosis (AS). The alternative activated subtype, M2, also plays various roles, such as directing Th2 humoral response, killing parasites, repairing tissues, and producing anti-inflammatory cytokines. M2 macrophages are regarded as inhibitors of AS. However, it is noteworthy that the distinction between M1 and M2 macrophages may not be absolutely definitive; many researchers consider the M1 and M2 subtypes as opposing extremes of the macrophage spectrum.
The classical activation of M1 macrophages by interferon-γ (IFN-γ) and LPS creates cells that can produce various pro-inflammatory chemokines and cytokines such as IL-6 and TNF-α. M2 macrophages, usually activated by IL-4, produce anti-inflammatory cytokines such as IL-10. Aside from their differential expression of opposing effector molecules, inducible nitric oxide synthase (iNOS) is expressed more in M1 macrophages, whereas arginase-1 (Arg-1) and mannose membrane receptor (MMR) are expressed more in M2 macrophages, reflecting the different immunological roles of these two populations. In this study, we chose IL-6, TNF-α, and iNOS as M1 macrophage markers, whose expression was induced by IFN-γ and LPS. We chose IL-10, Arg-1, and MMR as M2 macrophage markers, whose expression was induced by IL-4. These results are consistent with our previous work.
LPS, the primary glycolipid component found in the outer membranes of Gram-negative bacteria, can induce inflammatory responses, activate the complement system, and initiate the coagulation pathway. Many studies have confirmed that in the presence of IL-1 or IFN-γ, the LPS-induced defense reaction and killing ability could be augmented. Conversely, the pro-inflammatory effect of IFN-γ can be enhanced by the presence of LPS[15, 16]. Because we had been unable to stimulate macrophage subtype polarization using Hcy alone (data not shown), we decided to use a combination of Hcy and LPS.
In the presence of LPS, Hcy led to up-regulated expression of M1 macrophage markers (IL-6, TNF-α, and iNOS); the optimal Hcy concentration was 50 μmol/L. However, Hcy and LPS elicited no significant effects on the expression of M2 macrophage markers (IL-10, Arg-1, and MMR). No correlation between the concentration of Hcy and the expression of marker genes was observed. This was possibly due to higher Hcy concentrations leading to more cell death. We also found that a combination of Hcy and LPS could transform M2 subtype into M1. This phenomenon may help to explain the pro-atherosclerotic effects of Hcy.
Many studies have shown that Hcy can act as a promoter of AS by activating inflammatory immune reactions. The immuno-inflammation hypothesis is a generally accepted explanation for the mechanism of AS, and macrophages are believed to be important in this process. The differentiation of macrophages into different sub-populations has become a new exploratory area in the initiation and progression of AS. Zhang et al. have demonstrated that Hyperhomocysteinemia (HHcy) could accelerate AS and enhance Ly-6C Monocyte/Macrophage accumulation in the lesions of Tg-hCBS apoE−/−Cbs−/− mice. They also found that monocyte/macrophage accumulation in the lesions of Ly-6C-positive mice correlated positively with Hcy levels. However, little is known about the influence of Hcy on the polarization of cultured macrophages. In this study, we used a cell-based assay to demonstrate that Hcy could induce macrophage polarization into the pro-inflammatory phenotype, thereby providing further evidence in support of the model for Hcy-induced AS.
We investigated the synergistic effects of Hcy and LPS on the differentiation and conversion of RAW264.7 macrophages. The results showed that a combination of Hcy and LPS could induce macrophages to differentiate into the pro-inflammatory subtype. The differentiated anti-inflammatory subtype could also be converted to the pro-inflammatory subtype by combined treatment with Hcy and LPS. These findings provide new evidence for the role of Hcy in facilitating the progression of AS.
Inducible nitric oxide synthase
Mannose membrane receptor.
Sources of funding
This work was supported in part by the National Science Fund for Distinguished Young Scholars (81025002 to ZY) and the Natural Science Foundation of China (30871043 to ZY and 81100209 to YW).
- Galkina E, Ley K: Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009, 27: 165-10.1146/annurev.immunol.021908.132620.PubMedPubMed CentralView Article
- Ross R: Atherosclerosis is an inflammatory disease. Am Heart J. 1999, 138: 419-420. 10.1016/S0002-8703(99)70266-8.View Article
- Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105 (9): 1135-1143. 10.1161/hc0902.104353.PubMedView Article
- Linton MRF, Fazio S: Macrophages, inflammation, and atherosclerosis. Int J Obes. 2003, 27: S35-S40.View Article
- Weber C, Zernecke A, Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008, 8 (10): 802-815. 10.1038/nri2415.PubMedView Article
- Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32 (5): 593-604. 10.1016/j.immuni.2010.05.007.PubMedView Article
- Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25 (12): 677-686. 10.1016/j.it.2004.09.015.PubMedView Article
- Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001, 107 (6): 675-683. 10.1172/JCI10588.PubMedPubMed CentralView Article
- de Lawrence Koning A, Werstuck GH, Zhou J, Austin RC: Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003, 36 (6): 431-441. 10.1016/S0009-9120(03)00062-6.View Article
- Austin RC, Lentz SR, Werstuck GH: Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004, 11 (Suppl 1): S56-S64.PubMedView Article
- Zhang D, Fang P, Jiang X, Nelson J, Moore JK, Kruger WD, Berretta RM, Houser SR, Yang X, Wang H: Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res. 2012, 111 (1): 37-49. 10.1161/CIRCRESAHA.112.269472.PubMedPubMed CentralView Article
- Chen T, Liang X, He M, Wu Y, Yuan Z: Introduction and Identification of M1/M2 Phenotypes of RAW264.7. Mol Cardiol China. 2011, 2: 39-42.
- Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008, 8 (12): 958-969. 10.1038/nri2448.PubMedPubMed CentralView Article
- Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H: Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther. 2003, 100 (2): 171-194. 10.1016/j.pharmthera.2003.08.003.PubMedView Article
- Wan Y, Freeswick PD, Khemlani LS, Kispert PH, Wang SC, Su GL, Billiar TR: Role of lipopolysaccharide (LPS), interleukin-1, interleukin-6, tumor necrosis factor, and dexamethasone in regulation of LPS-binding protein expression in normal hepatocytes and hepatocytes from LPS-treated rats. Infect Immun. 1995, 63 (7): 2435-2442.PubMedPubMed Central
- Adams DO, Hamilton TA: The cell biology of macrophage activation. Annu Rev Immunol. 1984, 2 (1): 283-318. 10.1146/annurev.iy.02.040184.001435.PubMedView Article
- Zhang D, Jiang X, Fang P, Yan Y, Song J, Gupta S, Schafer AI, Durante W, Kruger WD, Yang X, Wang H: Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates athrosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation. 2009, 120 (19): 1893-1902. 10.1161/CIRCULATIONAHA.109.866889.PubMedPubMed CentralView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.